HCV Treatment
Milk Thistle Fails to Reduce Liver Inflammation in Non-responder Hepatitis C Patients
- Details
- Category: Alternative & Complementary Therapy
- Published on Tuesday, 17 July 2012 00:00
- Written by Liz Highleyman
The milk thistle extract silymarin did not reduce elevated alanine aminotransferase (ALT) levels more than placebo in a controlled trial of chronic hepatitis C patients who did not achieve sustained response to prior treatment, researchers reported in the July 18, 2012, Journal of the American Medical Association. 
New Study Will Test Simeprevir plus Daclatasvir for Previously Untreated Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 06 July 2012 00:00
- Written by Press Release
Researchers will soon begin testing an interferon-free dual oral regimen of simeprevir (better known as TMC435) plus daclatasvir (formerly BMS-790052) for treatment-naive genotype 1 chronic hepatitis C patients, co-developer Medivir announced last week.
Hepatitis C Treatment May Improve Liver Fibrosis Even Without a Cure
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 July 2012 00:00
- Written by Liz Highleyman
Experiencing a large decrease in hepatitis C virus (HCV) viral load after starting interferon-based therapy was associated with reduced liver inflammation and lower risk of fibrosis progression, even among patients who did not achieve sustained virological response, researchers reported in the June 12, 2012, advance edition of the American Journal of Gastroenterology.
Promising Proof-of-concept Data for Hepatitis C NS5A Inhibitor PPI-668
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 July 2012 00:00
- Written by Press Release
Presidio Pharmaceuticals' experimental hepatitis C virus (HCV) NS5A Inhibitor PPI-668 demonstrated potent antiviral activity and good tolerability in a Phase 1b proof-of-concept study of genotype 1 patients, the company reported last week.
Idenix Announces Promising Data for Hepatitis C Drugs IDX184 and IDX719
- Details
- Category: HCV Treatment
- Published on Friday, 29 June 2012 00:00
- Written by Press Release
Interim findings from a Phase 2b study show that 8 out of 9 genotype 1 chronic hepatitis C patients treated with Idenix Pharmaceuticals' experimental HCV polymerase inhibitor IDX184 with continued pegylated interferon/ribavirin through week 24 had undetectable viral load 4 weeks after competing therapy. Another trial found that the NS5A inhibitor IDX719 has activity against all HCV genotypes.
More Articles...
- New HCV Protease Inhibitor ACH-2684 Looks Good in Phase 1 Study
- Hepatitis C Treatment Reduces HIV Progression and Death in HIV/HCV Coinfected
- EASL 2012: Telaprevir 100% Effective for IL28B CC, Adding VX-222 Overcomes Unfavorable Genes
- EASL 2012: Ribavirin Dose Reduction Is Effective for Managing Anemia in Patients Using Boceprevir or Telaprevir
Web Design and Development by